This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Sarclisa (isatuximab)
General Description:
Sarclisa (isatuximab) is a monoclonal antibody used in combination therapies for the treatment of relapsed or refractory multiple myeloma (RRMM) in adult patients. It is administered either with pomalidomide and dexamethasone or with carfilzomib and dexamethasone.
Sarclisa works by targeting CD38, a protein expressed on multiple myeloma cells, and inducing direct tumor cell death while also engaging the immune system to attack cancer cells. This dual mechanism provides an effective option for patients who have relapsed or are refractory to prior treatments.
Disease Indications:
Multiple Myeloma
Manufacturer:
Sanofi
Usage:
Intravenous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
Package:
• Single-dose vial × 100 mg/5 mL
• Single-dose vial × 500 mg/25 mL
Shipping:
Cold Chain Shipping
Biologic medicines such as Sarclisa are sensitive to heat, light, and handling. To maintain stability and efficacy, Sarclisa is shipped under strict cold chain conditions using specialized medical couriers with temperature-controlled packaging and vehicles.
Cold chain delivery may be slightly more expensive than standard shipping, but it ensures the medicine arrives uncompromised and fully effective.
How to Access Sarclisa (isatuximab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Sarclisa (isatuximab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
